Barinthus Biotherapeutics (BRNS) Stock Overview
Engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BRNS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Barinthus Biotherapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.63 |
| 52 Week High | US$2.92 |
| 52 Week Low | US$0.56 |
| Beta | -0.62 |
| 1 Month Change | -4.55% |
| 3 Month Change | -14.75% |
| 1 Year Change | -36.36% |
| 3 Year Change | -74.07% |
| 5 Year Change | n/a |
| Change since IPO | -95.53% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Barinthus Biotherapeutics plc (NASDAQ:BRNS) Stock's 29% Jump Looks Justified
Jun 22
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Apr 11Barinthus Biotherapeutics plc (NASDAQ:BRNS) Surges 33% Yet Its Low P/S Is No Reason For Excitement
Jan 10Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%
Nov 19Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?
Aug 31Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Apr 05We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth
Jul 07Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality
Nov 17Vaccitech promotes Gemma Brown to CFO
Sep 20Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts
Aug 15Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 13Vaccitech GAAP EPS of $0.41, revenue of $17.06M
Aug 09Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%
May 19Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Apr 03Vaccitech: The Next Big Vaccine Trade
Jun 27Shareholder Returns
| BRNS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | -1.8% | -0.7% |
| 1Y | -36.4% | 23.0% | 16.5% |
Return vs Industry: BRNS underperformed the US Biotechs industry which returned 23% over the past year.
Return vs Market: BRNS underperformed the US Market which returned 16.5% over the past year.
Price Volatility
| BRNS volatility | |
|---|---|
| BRNS Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BRNS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BRNS's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 105 | Bill Enright | www.barinthusbio.com |
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S.
Barinthus Biotherapeutics plc Fundamentals Summary
| BRNS fundamental statistics | |
|---|---|
| Market cap | US$25.73m |
| Earnings (TTM) | -US$66.43m |
| Revenue (TTM) | n/a |
Is BRNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRNS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$133.00k |
| Gross Profit | -US$133.00k |
| Other Expenses | US$66.30m |
| Earnings | -US$66.43m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BRNS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/20 00:22 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Barinthus Biotherapeutics plc is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Yi Chen | H.C. Wainwright & Co. |
| Matthew Harrison | Morgan Stanley |